Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Fiocco, Ugo ^a   Sfriso, Paolo ^a   Oliviero, Francesca ^a   Roux Lombard, Pascale ^b   Scagliori, Elena ^a   Cozzi, Luisella ^a   Lunardi, Francesca ^a   Calabrese, Fiorella ^a   Vezzù, Maristella ^a   Dainese, Serena ^a   Molena, Beatrice ^a   Scanu, Anna ^a   Nardacchione, Roberto ^c   Rubaltelli, Leopoldo ^a   Dayer, Jean Michel ^d   Punzi, Leonardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Abano Terme Hospital   (Italy)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD3 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CHLORDANE; ENDOGLIN; ETANERCEPT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IL6 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 22; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; JOINT EFFUSION; KNEE; LEUKOCYTE COUNT; MONONUCLEAR CELL; PSORIATIC ARTHRITIS; RELIABILITY; SINGLE BLIND PROCEDURE; SYNOVIAL FLUID; SYNOVITIS; DRUG ANTAGONISM; DRUG MONITORING; INTRAARTICULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; STANDARD; SYNOVIUM;

ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKINS; KNEE JOINT; LEUKOCYTE COUNT; REPRODUCIBILITY OF RESULTS; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954686526     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3090     Document Type: Article

References (62)

1. Gladman DD. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 2003, 33:29-37. 10.1053/sarh.2002.50024, 12920694.
2. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001, 28:1842-1846.
3. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001, 28:1041-1044.
4. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O. Reduced synovial membrane macrophage numbers ELAM1 expression and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993, 36:893-900. 10.1002/art.1780360705, 7686370.
5. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived factor kB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000, 43:1244-1256. 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2, 10857783.
6. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544-1552.
7. van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006, 65:1551-1557. 10.1136/ard.2005.050963, 1798447, 16728461.
8. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831. 153764, 12639988.
9. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390. 10.1016/S0140-6736(00)02530-7, 10972371.
10. Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004, 63:156-161. 10.1136/ard.60.3.233, 1754892, 14722204.
11. Kane D, FitzGerald O. Tumour necrosis facter alpha in psoriasis and psoriatic arthritis: a clinical genetic, and histopatholic perspective. Curr Rheumatol Rep 2004, 6:292-298. 10.1007/s11926-004-0041-0, 15251081.
12. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005, 64 Suppl 2:ii26-ii29. 10.1136/ard.2004.031740, 1766860, 15708930.
13. Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 2007, 6:524-528. 10.1016/j.autrev.2006.12.003, 17854743.
14. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, Schreiber S, Kabelitz D, Lim HW, Voorhees JJ, Christophers E, Elder JT, Weichenthal M. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008, 128:1653-1661. 10.1038/sj.jid.5701255, 2739284, 18219280.
15. Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J, Bruce IN, Barton A. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008, 58:3705-3709. 10.1002/art.24128, 19035472.
16. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009, 11:214. 10.1186/ar2580, 2688229, 19232079.
17. Ritchlin CT, Proulx S, Schwarz ES. Translational perspectives on psoriatic arthritis. J Rheumatol Suppl 2009, 83:30-34. 10.3899/jrheum.090219, 19661536.
18. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells:human T-helper cell differentiation revisited. Immunol Rev 2008, 226:132-146. 10.1111/j.1600-065X.2008.00714.x, 19161421.
19. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. Interleukin-22, a T(H)17 cytokine mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651. 10.1038/nature05505, 17187052.
20. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX, Nau F, Guillet G, Dagregorio G, Yssel H, Lecron JC, Morel F. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007, 150:407-415. 10.1111/j.1365-2249.2007.03511.x, 2219373, 17900301.
21. de Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008, 35:1443-1448.
22. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith SA, Ritchlin CT. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008, 67:296-301. 10.1136/ard.2007.076091, 17967829.
23. Fisher BA, Keat A. Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis?. J Rheumatol 2006, 33:1934-1935.
24. Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsøe B, Torp-Pedersen S. A randomized controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 2006, 35:341-345. 10.1080/03009740600844530, 17062431.
25. van der Bijl AE, Teng YK, van Oosterhout M, Breedveld FC, Allaart CF, Huizinga TW. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial. Arthritis Rheum 2009, 61:974-978. 10.1002/art.24513, 19565559.
26. Fiocco U, Sfriso P, Nardacchione R, Sovran F, Scagliori E, Cozzi L, Vezzù M, Bertolini D, Oliviero F, Botsios C, Piccoli A, Di Maggio A, Rubaltelli L, Punzi L. Evaluation of the efficacy and safety of repeated intra-articular etanercept injections in Resistant Knee Joint Synovitis. Arthritis Rheum 2007, 56:S592.
27. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, . CASPAR Study Group Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673. 10.1002/art.21972, 16871531, CASPAR Study Group.
28. Thompson PW, Silman AJ, Kirwan JR, Currey LF. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum 1987, 30:618-623. 10.1002/art.1780300603, 3111490.
29. Fiocco U, Ferro F, Vezzu M, Cozzi L, Checchetto C, Sfriso P, Botsios C, Ciprian L, Armellin G, Nardacchione R, Piccoli A, Todesco S, Rubaltelli L. Rheumatoid and psoriatic knee synovitis: clinical grey scale and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005, 64:899-905. 10.1136/ard.2004.025585, 1755540, 15567814.
30. Ritchie DM, Boyle JA, Mcinnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968, 37:393-406.
31. Punzi L, Bertazzolo N, Pianon M, Rizzi E, Rossini P, Gambari PF. Value of synovial fluid interleukin-1 beta determination in predicting the outcome of psoriatic arthritis. Ann Rheum Dis 1996, 55:642-644. 10.1136/ard.55.9.642, 1010262, 8882136.
32. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997, 24:518-523.
33. Canete JD, Martinez SE, Farres J, Sanmarti R, Blay M, Gomez A, Salvador G, Muñoz-Gómez J. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon-γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000, 59:263-268. 10.1136/ard.59.4.263, 1753106, 10733472.
34. Gu J, Rihl M, Märker-Hermann E, Baeten D, Kuipers JG, Song YW, Maksymowych WP, Burgos-Vargas R, Veys EM, De Keyser F, Deister H, Xiong M, Huang F, Tsai WC, Yu DT. Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol 2002, 29:2159-2164.
35. Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, Verbruggen G, De Keyser F, Elewaut D. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010, 69:618-623. 10.1136/ard.2009.107649, 19196728.
36. Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007, 34:2285-2290.
37. Vandooren B, Noordenbos T, Ambarus C, Krausz S, Cantaert T, Yeremenko N, Boumans M, Lutter R, Tak PP, Baeten D. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis including psoriatic arthritis. Arthritis Rheum 2009, 60:966-975. 10.1002/art.24406, 19333931.
38. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthritis. Clin Exp Rheumatol 2009, 27:22-27.
39. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992, 90:772-779. 10.1172/JCI115950, 329929, 1522232.
40. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation?. Ann Rheum Dis 2004, 63:1186-1194. 10.1136/ard.2004.020529, 1754785, 15082471.
41. Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008, 153:188-195. 10.1111/j.1365-2249.2008.03691.x, 2492901, 18549443.
42. Ross EL, D'Cruz D, Morrow WJ. Localized monocyte chemotactic protein-1 production correlates with T cell infiltration of synovium in patients with psoriatic arthritis. J Rheumatol 2000, 27:2432-2443.
43. Szodoray P, Alex P, Chappell-Woodward CM, Madland TM, Knowlton N, Dozmorov I, Zeher M, Jarvis JN, Nakken B, Brun JG, Centola M. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology 2007, 46:417-425. 10.1093/rheumatology/kel306, 16936328.
44. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, Nojima Y. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52:1037-1046. 10.1002/art.20965, 15818686.
45. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, Matthys P. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009, 60:390-395. 10.1002/art.24220, 19180498.
46. Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, Veys EM, Baeten D. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005, 52:3898-3909. 10.1002/art.21426, 16329106.
47. van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, Zwinderman AH, Dijkmans BA, Tak PP. A prospective randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 2009, 68:1303-1309. 10.1136/ard.2008.091389, 2703703, 18647851.
48. Rooney T, Roux-Lombard P, Veale DJ, Fitzgerald O, Dayer JM, Bresnihan B. Synovial tissue and serum biomarkers of disease activity therapeutic response and radiographic progression. Analysis of a proof-of-concept randomized clinical trial of cytokine blockade. Ann Rheum Dis 2010, 69:706-714. 10.1136/ard.2009.108324, 19460761.
49. Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 2000, 19:101-105. 10.1007/s002960050111, 10776688.
50. Macchioni P, Boiardi L, Cremonesi T, Battistel B, Casadei-Maldini M, Beltrandi E, Mancini R, Salvarani C. The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol Int 1998, 18:27-33. 10.1007/s002960050050, 9672996.
51. Gratacos J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 2007, 66:493-749. 10.1136/ard.2006.060079, 1856049, 17179176.
52. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008, 159:322-330. 10.1111/j.1365-2133.2008.08628.x, 18503600.
53. Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol 2008, 35:1426-1430.
54. Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewé R, Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy H, Aletaha D, Inman RD, Kraus VB, Kvien TK, van der Heijde D. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis psoriatic arthritis and ankylosing spondylitis and recommendations for study design. J Rheumatol 2009, 36:1792-1799. 10.3899/jrheum090347, 19671814.
55. Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Ito S, Suguro T, Sumida T. Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol 2008, 18:15-22. 10.1007/s10165-007-0015-y, 18092129.
56. Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006, 65 Suppl 3:iii29-iii33. 10.1136/ard.2006.058529, 1798387, 17038468.
57. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008, 205:2491-2497. 10.1084/jem.20072707, 2571924, 18936235.
58. Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, Young DA. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010, 62:430-440. 10.1002/art.27203, 20112373.
59. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007, 56:2936-2946. 10.1002/art.22866, 2323677, 17763419.
60. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10:864-871. 10.1038/ni.1770, 19578368.
61. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863. 10.1038/ni.1767, 19578369.
62. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, Doherty JM, Mills JC, Colonna M. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725. 10.1038/nature07537, 18978771.